SavedAdd your journal

Journals / Organic Communications / 2020 / Cilt: 13 - Sayı: 2

Evaluation of new 2-hydroxy-N-(4-oxo-2-substituted phenyl-1,3- thiazolidin-3-yl)-2-phenylacetamide derivatives as potential antimycobacterial agents

Özlen GÜZEL AKDEMİR
Kübra DEMİR-YAZICI
Muhammed TRAWALLY
Serap İpek Dingiş BİRGÜL
Atilla AKDEMİR
Pages
33–50
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Eventually, molecular modelling studies indicated that at least part of the mechanism of action of these compounds may be mediated by inhibition of MtInhA.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A small collection of 2-hydroxy-N-(5-methyl/nonsubstituted 4-oxo-2-substituted phenyl-1,3-thiazolidin-3- yl)-2-phenylacetamides (3-16) was synthesized from the cyclocondensation of 2-hydroxy-2-phenyl-N'- [(substitutedphenyl)methylene]acetohydrazides (2) and mercaptoethanoic acid or 2-mercaptopropanoic acid, characterized with spectral and elemental analysis.
📊
Key Findings & Data:In order to explore their antimycobacterial potential, newly synthesized fourteen compounds were screened for their inhibitory activity against Mycobacterium tuberculosis strain H37Rv at 6.25 μg/mL with in-vitro primary tests.
💡
Conclusion & Impact:Eventually, molecular modelling studies indicated that at least part of the mechanism of action of these compounds may be mediated by inhibition of MtInhA.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

A small collection of 2-hydroxy-N-(5-methyl/nonsubstituted 4-oxo-2-substituted phenyl-1,3-thiazolidin-3- yl)-2-phenylacetamides (3-16) was synthesized from the cyclocondensation of 2-hydroxy-2-phenyl-N'- [(substitutedphenyl)methylene]acetohydrazides (2) and mercaptoethanoic acid or 2-mercaptopropanoic acid, characterized with spectral and elemental analysis. In order to explore their antimycobacterial potential, newly synthesized fourteen compounds were screened for their inhibitory activity against Mycobacterium tuberculosis strain H37Rv at 6.25 μg/mL with in-vitro primary tests. Compound 7 was found to provide the highest inhibition (98%) M. tuberculosis strain H37Rv, while most of the new derivatives showed different inhibition ratios. For the search of the putative targets which are considered as related to the antimycobacterial activity of these molecules, docking studies were performed. With molecular dynamic simulations, further possible interactions between ligands and the active site of the selected enzymes were investigated. Eventually, molecular modelling studies indicated that at least part of the mechanism of action of these compounds may be mediated by inhibition of MtInhA.

🔖

Cite This Article

AKDEMİR, Ö. G., DEMİR-YAZICI, K., TRAWALLY, M., BİRGÜL, S. İ. D., AKDEMİR, A. (2020). Evaluation of new 2-hydroxy-N-(4-oxo-2-substituted phenyl-1,3- thiazolidin-3-yl)-2-phenylacetamide derivatives as potential antimycobacterial agents. Organic Communications, Cilt: 13 - Sayı: 2, 33–50. https://ajindex.com/articles/288455

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Smith, I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev. 2003, 16(3), 463-496
  2. World Health Organization. Tuberculosis Homepage. available online: https://www.who.int/newsroom/fact-sheets/detail/tuberculosis (accessed on 5 May 2020
  3. World Health Organization. Global tuberculosis reports. 2019, 23, 1-4
  4. World Health Organization. Tuberculosis Fact Sheets. Available online: https://www.who.int/newsroom/fact-sheets/detail/tuberculosis (accessed on 5 May 2020)
  5. Glaziou, P. Predicted impact of the COVID-19 pandemic on global tuberculosis deaths in 2020. medRxiv. 2020, 5, 1-7
  6. Zhang, Y.; Post-Martens, K.; Denkin, S. New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discovery Today. 2006, 11, 21–27
  7. Chan, E. D. Current medical treatment for tuberculosis. BMJ. 2002, 325(7375), 1282–1286
  8. Gygli, S. M.; Borrell, S.; Trauner, A.; Gagneux, S. Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. FEMS Microbiol. Rev. 2017, 011, 354–373
  9. Kanetaka, H.; Koseki, Y.; Taira, J.; Umei, T.; Komatsu, H.; Sakamoto, H.; Gulten, G.; Sacchettini, J. C.; Kitamura, M.; Aoki, S. Discovery of InhA inhibitors with anti-mycobacterial activity through a matched molecular pair approach. Eur. J. Med. Chem. 2015, 94, 378–385
  10. Duan, X.; Xiang, X.; Xie, J. Crucial components of mycobacterium type II fatty acid biosynthesis (Fas-II) and their inhibitors. FEMS Microbiol. Lett. 2014, 360 (2), 87–99
  11. Quémard, A.; Sacchettini, J. C.; Dessen, A.; Vilcheze, C.; Bittman, R.; Jacobs, W. R.; Blanchard, J. S. Enzymatic Characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 1995, 34 (26), 8235–8241
  12. Vigorita, M. G.; Ottanà, R.; Monforte, F.; Maccari, R.; Trovato, A.; Monforte, M. T.; Taviano, M. F. Synthesis and antiinflammatory, analgesic activity of 3,3’-(1,2-ethanediyl)-bis[2-aryl-4-thiazolidinone] chiral compounds. Bioorg. Med. Chem. Lett. 2001, 11 (21), 2791–2794
  13. Vicini, P.; Geronikaki, A.; Anastasia, K.; Incerti, M.; Zani, F. Synthesis and antimicrobial activity of novel 2-thiazolylimino-5-arylidene-4-thiazolidinones. Bioorganic Med. Chem. 2006, 14 (11), 3859–3864
  14. D’Ascenzio, M.; Bizzarri, B.; De Monte, C.; Carradori, S.; Bolasco, A.; Secci, D.; Rivanera, D.; Faulhaber, N.; Bordón, C.; Jones-Brando, L. Design, Synthesis and biological characterization of thiazolidin-4-one derivative